Genesis Therapeutics

Genesis Therapeutics (Genesis Molecular AI) is an AI drug-discovery company built around its GEMS platform, which combines deep learning with physics-based simulation to design small molecules — especially for "hard-to-drug" targets that resist conventional medicinal chemistry. Rather than only running its own pipeline, Genesis has struck research partnerships with major pharma companies including Eli Lilly, Genentech, Gilead, and Incyte (Incyte expanded its collaboration with an additional payment), validating the platform through paid collaborations. The company has raised more than 600 million dollars. Genesis illustrates a common AI-biotech model: sell platform access and partnerships to established pharma while advancing selected internal programs. As always, computational designs are hypotheses that must clear synthesis, testing, and the long clinical road before they become medicines.